Table 1.
Cohort’s baseline demographics, disease characteristics and previous treatment data.
Table 2.
Panobinostat and bortezomib dosing schedules at treatment initiation.
Fig 1.
Kaplan-Meier estimates of progression free survival (PFS) for PanBorDex patients.
(a) PFS of all patients in the cohort. (b) PFS according to refractoriness to PIs and IMiDs. (c) PFS according to depth of response. The PFS was significantly longer in non-refractory patients (p<0.001) and in patients who achieved a VGPR (p = 0.003). Abbreviations: PFS, progression-free survival; PI, proteasome inhibitor; IMiD, immunomodulatory agent; SD, stable disease; MR, minimal response; PR, partial response; VGPR, very good partial response.
Fig 2.
Kaplan-Meier estimates of progression free survival (PFS) for PanBorDex patients according to dosing.
(a) PFS per PANORAMA-1 or attenuated dosing. (b) PFS according to PAN dosing schedules. (c) PFS according to BTZ dosing schedule. There was a trend for longer PFS in the PAN 20mg BW group and BTZ once weekly group. Abbreviations: PFS, progression-free survival; PAN, panobinostat; BTZ, bortezomib; TW, three times a week; BW; twice weekly.
Table 3.
Overall response rate according to dosing.
Table 4.
Adverse event (AEs) of special interest observed during PanBorDex treatment, graded according to CTCAE 4.0 toxicity grading criteria.